South Korea · Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 826.18 billion. The enterprise value is 860.10 billion.
| Market Cap | 826.18B |
| Enterprise Value | 860.10B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Medy-Tox has 7.02 million shares outstanding. The number of shares has decreased by -2.69% in one year.
| Current Share Class | 7.02M |
| Shares Outstanding | 7.02M |
| Shares Change (YoY) | -2.69% |
| Shares Change (QoQ) | -17.19% |
| Owned by Insiders (%) | 19.21% |
| Owned by Institutions (%) | 11.62% |
| Float | 5.23M |
Valuation Ratios
The trailing PE ratio is 41.55 and the forward PE ratio is 21.59.
| PE Ratio | 41.55 |
| Forward PE | 21.59 |
| PS Ratio | 3.52 |
| PB Ratio | 1.78 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | 17.87 |
| P/OCF Ratio | 15.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.86, with an EV/FCF ratio of 18.60.
| EV / Earnings | 47.21 |
| EV / Sales | 3.67 |
| EV / EBITDA | 18.86 |
| EV / EBIT | 33.72 |
| EV / FCF | 18.60 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.80 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.97 |
| Debt / FCF | 1.66 |
| Interest Coverage | 10.85 |
Financial Efficiency
Return on equity (ROE) is 3.76% and return on invested capital (ROIC) is 2.11%.
| Return on Equity (ROE) | 3.76% |
| Return on Assets (ROA) | 1.96% |
| Return on Invested Capital (ROIC) | 2.11% |
| Return on Capital Employed (ROCE) | 3.80% |
| Revenue Per Employee | 332.81M |
| Profits Per Employee | 25.84M |
| Employee Count | 705 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.79 |
Taxes
| Income Tax | -247.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.65% in the last 52 weeks. The beta is 0.28, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -34.65% |
| 50-Day Moving Average | 124,010.00 |
| 200-Day Moving Average | 140,464.50 |
| Relative Strength Index (RSI) | 38.49 |
| Average Volume (20 Days) | 41,055 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 234.63 billion and earned 18.22 billion in profits. Earnings per share was 2,832.89.
| Revenue | 234.63B |
| Gross Profit | 134.80B |
| Operating Income | 18.74B |
| Pretax Income | 17.48B |
| Net Income | 18.22B |
| EBITDA | 38.85B |
| EBIT | 18.74B |
| Earnings Per Share (EPS) | 2,832.89 |
Balance Sheet
The company has 45.69 billion in cash and 76.55 billion in debt, giving a net cash position of -30.86 billion or -4,396.43 per share.
| Cash & Cash Equivalents | 45.69B |
| Total Debt | 76.55B |
| Net Cash | -30.86B |
| Net Cash Per Share | -4,396.43 |
| Equity (Book Value) | 464.93B |
| Book Value Per Share | 65,799.27 |
| Working Capital | 70.87B |
Cash Flow
In the last 12 months, operating cash flow was 54.40 billion and capital expenditures -8.16 billion, giving a free cash flow of 46.24 billion.
| Operating Cash Flow | 54.40B |
| Capital Expenditures | -8.16B |
| Free Cash Flow | 46.24B |
| FCF Per Share | 6,588.05 |
Margins
Gross margin is 57.45%, with operating and profit margins of 7.99% and 8.18%.
| Gross Margin | 57.45% |
| Operating Margin | 7.99% |
| Pretax Margin | 7.45% |
| Profit Margin | 8.18% |
| EBITDA Margin | 16.56% |
| EBIT Margin | 7.99% |
| FCF Margin | 19.71% |
Dividends & Yields
This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.93%.
| Dividend Per Share | 1,100.00 |
| Dividend Yield | 0.93% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 43.89% |
| Buyback Yield | 2.69% |
| Shareholder Yield | 3.61% |
| Earnings Yield | 2.21% |
| FCF Yield | 5.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 7.07 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.07 |
| Piotroski F-Score | 5 |